GlassScriptPhysician profile
David R Hensley
NPI 1144376419
$427,622.68
in general payments reported to CMS, 2019-2025
44 companies · $40K in 2025
The $40K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82K · 2020: $29K · 2021: $29K · 2022: $76K · 2023: $120K · 2024: $52K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $162K · Food and Beverage: $19K · Travel and Lodging: $12K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,498 · Consulting Fee: $6,010 · Honoraria: $5,400 · Education: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $162,029.00 |
| Food and Beverage | $19,361.89 |
| Travel and Lodging | $11,930.67 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,498.00 |
| Consulting Fee | $6,010.00 |
| Honoraria | $5,400.00 |
| Education | $529.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $139,750.72 | 2019-2025 | Otezla, Otezla |
| Abbvie INC. | $123,306.83 | 2019-2025 | |
| Celgene Corporation | $42,766.02 | 2019 | |
| Sun Pharmaceutical Industries INC. | $34,954.28 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Dermavant Sciences, INC. | $33,852.83 | 2022-2024 | Vtama |
| Lilly USA, LLC | $22,248.12 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Organon LLC | $5,676.62 | 2025 | Vtama |
| Janssen Biotech, INC. | $4,263.77 | 2019-2025 | Tremfya, Simponi, Stelara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $2,927.15 | 2019-2025 | Cabtreo, Arazlo, Siliq |
| Novartis Pharmaceuticals Corporation | $2,401.16 | 2019-2025 | |
| Biofrontera INC. | $2,223.91 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Incyte Corporation | $2,011.08 | 2022-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $1,472.68 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,455.27 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $1,305.13 | 2019-2025 | Bimzelx, Cimzia |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hensley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.